Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
First Trust NYSE Arca Biotechnology ETF (FBT) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
First Trust NYSE Arca Biotechnology ETF (FBT) - free report >>
Image: Bigstock
Biotech ETF (FBT) Hits New 52-Week High
For investors seeking momentum, First Trust NYSE Arca Biotechnology Index Fund (FBT - Free Report) is probably on radar. The fund just hit a 52-week high and is up about 35% from its 52-week low price of $121.68/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
FBT in Focus
First Trust NYSE Arca Biotechnology Index Fund provides exposure to the companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It charges 30 bps in annual fees (see: all the Healthcare ETFs here).
Why the Move?
The biotech space of the broad healthcare market has been an area to watch, given the return of investors’ risk appetite. Investors are flocking to the most beaten-down sectors like biotech, which has been marred by higher interest rates, as these offer compelling buy points.
More Gains Ahead?
Currently, FBT has a Zacks ETF Rank #2 (Buy) with a High risk outlook, suggesting that the outperformance could continue in the months ahead. However, many spaces that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.